Case Report

Refractory Thrombocytopenia Responds to Octreotide Treatment in a Case of Evans Syndrome with Gastric Neuroendocrine Tumor

Kocfa Chung-Delgado,1 Alejandro Revilla-Montag,1 Sonia Guillén-Bravo,1 Hugo Ríos-Díaz,2 and José C. Alva-Muñoz3

1 Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima 33, Peru
2 Hematology Department, Hospital Nacional “Edgardo Rebagliati Martins”, Lima 33, Peru
3 Clinical Pathology Department, Hospital Nacional “Edgardo Rebagliati Martins”, Lima 33, Peru

Correspondence should be addressed to Kocfa Chung-Delgado; kocfachung@gmail.com

Received 20 May 2013; Accepted 8 July 2013

A 37-year-old woman with history of Evans Syndrome with poor response to high-dose corticoid treatment presented to the emergency department with gastrointestinal and vaginal bleeding. The patient was later diagnosed with severe thrombocytopenia and a stage G1, well-differentiated gastric neuroendocrine tumor, confirmed by a biopsy. A total gastrectomy was performed to eradicate the tumor. After being treated with a total splenectomy for her Evans Syndrome with no clinical or laboratory improvement, she began regular treatment with octreotide on the basis of a possible hepatic metastasis. Days after the initiation of the octreotide, an increase in the platelet count was evidenced by laboratory findings, from 2,000 platelets/mm³ to 109,000 platelets/mm³. Weeks later, the hepatic metastasis is discarded by a negative octreotide-body scan, and the octreotide treatment was interrupted. Immediately after the drug interruption, a progressive and evident descent in the platelet count was evidenced (4000 platelets/mm³). The present case report highlights the possible association between octreotide treatment and a severe thrombocytopenia resistant to conventional treatment.

1. Background

Evans Syndrome is a condition involving the simultaneous or sequential presence of the following conditions: autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura. In both cases, the red blood cells or the platelets are matched with autoantibodies to begin their process of opsonization and their evident premature destruction by the reticuloendothelial system. Evans Syndrome is a chronic condition which is characterized by the presence of flares and exacerbations [1]. Many treatment options are available for this condition; however, in many cases, the disease might require splenectomy as a second-line treatment [2].

On the other hand, a carcinoid tumor is a rare type of neoplasm derived from enterochromaffin-like cells. Because of intrinsic properties, these tumors have the ability of secreting high quantities of hormones such as serotonin, histamine, gastrin, and prostaglandins, among others; serotonin-secreting cells being the most common amongst them [3]. The clinical presentation of the carcinoid-derived tumors has been associated with multiple paraneoplastic syndromes [4, 5].

The following case report presents a patient with history of Evans Syndrome with poor response to high-dose corticoid treatment, associated with the presence of a gastric neuroendocrine carcinoid tumor, which has evolved favorably with the use of octreotide.

2. Case Presentation

A 37-year-old woman with history of inactive Evans Syndrome with poor response to high-dose corticoid treatment presented to the emergency department with sudden...
Table 1: Test results for initial and differential diagnoses.

| Laboratory exam | Result          | Reference values |
|-----------------|-----------------|------------------|
| ANA             | Negative        | >INM 02          |
| ANCA            |                 |                  |
| MPO             | Negative        | >INM 08          |
| PR3             | Negative        | >INM 08          |
| Polyspecific direct coombs | Positive (3+) | —                 |
| Monospecific direct coombs | IgG Positive (3+) | —                 |
|                 | IgM Negative    | —                 |
|                 | IgA Negative    | —                 |
|                 | C3d Positive    | (2+)              |
|                 | C3c Negative    | —                 |
| Chromogranin A  | 142.0 ng/mL     | 1.9–15.0         |
| Rheumatoid factor | Negative      | >INM 05          |
| Gastrin         | 927.0 ng/L      | 0–100            |
| VIH 1-2 Ab + Ag p24 | Not reactive | —                 |
| Haptoglobin     | 99 mg/dL        | 5–220            |
| Full hepatitis panel (HBV/HCV) | Not reactive | —                 |
| CMV             | IgG negative    | —                 |
|                 | IgM negative    | —                 |
| HSV 1 and 2     | IgG negative    | —                 |
|                 | IgM negative    | —                 |
| VDRL            | Not reactive    | >INM 10          |
| Bone marrow aspiration/biopsy | Hyperplastic bone marrow with signs of peripheral thrombocytosis | — |

Case Reports in Hematology

After unsuccessful treatment with vincristine, danazol, cyclophosphamide and cyclosporine, the patient underwent a total splenectomy as a second-line treatment to her Evans Syndrome which had a last platelet count of 5,000 platelets/mm³. The splenectomy had a poor response. The pathology of the spleen showed moderate congestion of the red pulp without any additional alterations.

Seven weeks later, the patient went through a total gastrectomy as a definite treatment for her NET after repeated episodes of hematemesis. Her presurgical exams showed the following results: gastrin = 927 ng/L (1–100 ng/L); 5-hydroxyindoleacetic acid 5-HIAA = 2.1 mg/24 h (0–10 mg/24 h); chromogranin A = 142 ng/mL (1.9–15 ng/mL). The pathology of the surgical specimen confirmed the initial diagnosis: carcinoid NET, stage 1, with infiltration to the subserosal layer, associated with autoimmune atrophic gastritis (Figures 1 and 2). The immunohistochemistry exam tested positive for chromogranin A (Figure 3), positive for CD56 marker, (Figure 5), positive for CD8 marker and negative for CD4 marker.

The patient was prescribed high-dose corticoids, immunoglobulin G, and rituximab but remained hospitalized due to persistent severe thrombocytopenia. Her postsurgical exam values were: gastrin = 26 ng/L; chromogranin A = 3.2 ng/mL.

Two months later, the patient was reevaluated due to acute abdominal pain. Nodular hepatic lesions and severe hematemesis, persistent vaginal bleeding and severe thrombocytopenia. A gastric biopsy taken by upper endoscopy revealed a stage GI well-differentiated infiltrative neuroendocrine tumor (NET), compatible with a carcinoid tumor. Other possible diagnoses such as chronic or atypical infections, rheumatoid diseases and other bone marrow pathologies were discarded (Table 1).

After unsuccessful treatment with vincristine, danazol, cyclophosphamide and cyclosporine, the patient underwent a total splenectomy as a second-line treatment to her Evans Syndrome which had a last platelet count of 5,000 platelets/mm³. The splenectomy had a poor response. The pathology of the spleen showed moderate congestion of the red pulp without any additional alterations.

Seven weeks later, the patient went through a total gastrectomy as a definite treatment for her NET after repeated episodes of hematemesis. Her presurgical exams showed the following results: gastrin = 927 ng/L (1–100 ng/L); 5-hydroxyindoleacetic acid 5-HIAA = 2.1 mg/24 h (0–10 mg/24 h); chromogranin A = 142 ng/mL (1.9–15 ng/mL). The pathology of the surgical specimen confirmed the initial diagnosis: carcinoid NET, stage 1, with infiltration to the subserosal layer, associated with autoimmune atrophic gastritis (Figures 1 and 2). The immunohistochemistry exam tested positive for chromogranin A (Figure 3), positive for CD56 marker, (Figure 5), positive for CD8 marker and negative for CD4 marker.

The patient was prescribed high-dose corticoids, immunoglobulin G, and rituximab but remained hospitalized due to persistent severe thrombocytopenia. Her postsurgical exam values were: gastrin = 26 ng/L; chromogranin A = 3.2 ng/mL.

Two months later, the patient was reevaluated due to acute abdominal pain. Nodular hepatic lesions and severe
thrombocytopenia (2,000 platelets/mm$^3$) were found during the workup. Due to the high suspicion of hepatic metastasis of the NET, she was started on octreotide, 50 μg/8 h subcutaneous (SQ). Immediately after the first doses of octreotide, a constant increase in the platelet count was evidenced in the CBC, reaching 109,000 platelets/mm$^3$ (Figure 6). She was discharged with the same dosage of octreotide.

Over the following months, the patient showed clinical improvement. She was then changed to octreotide LAR depot medication, 40 mg every 30 days. Consequently, over the following 4 weeks, the platelet count decreased to 2,400 platelets/mm$^3$. She was readmitted into the emergency department with petechiae on her thorax and limbs. Conventional octreotide at 50 μg/8 h SQ was started until the possible hepatic metastasis was discarded. An elevation of platelet count to 164,000 platelets/mm$^3$ was seen. A complete set of exams were executed to rule out any residual activity of the NET: chromogranin A = 4.8 ng/mL; 5-HIAA = 2.4 mg/24 h; octreotide-Tc99 full-body scan negative, PET-SCAN negative for somatostatin-secreting lesions. With the lab and image results, the Endocrinology Department discarded the possibility of active NET, consequently discontinuing the administration of octreotide.

An abrupt fall in the platelet count was noted over the following 5 days (4,000 platelets/mm$^3$) after the discontinuation of octreotide (Figure 7).

3. Discussion and Conclusions

We report the case of a 37-year-old woman with Evans Syndrome which responded poorly to conventional first-line treatment and an infiltrative gastric neuroendocrine tumor (NET), stage 1, diagnosed by gastric biopsy and immunohistochemistry.

Evans Syndrome is an autoimmune condition which attacks erythrocytes and thrombocytes. It is most frequently found as an idiopathic presentation. It may also be evident simultaneously during the course of other diseases [6], such as a paraneoplastic syndrome of aggressive tumors.

First and foremost, at a first glance, it is clear that there is a positive response of the platelet count to the administration of octreotide. Octreotide is a somatostatin analogue which has been widely used for the treatment of NETs and upper gastrointestinal hemorrhage. It acts directly upon the somatostatin receptors and inhibits its hormonal secretion [7]. It is considered a first-line treatment for the control of symptoms in carcinoid tumors [8]. In this case, it may be possible that octreotide itself is responsible for the temporary remission of the idiopathic thrombocytopenia purpura (ITP). It may be behaving with some type of immunomodulatory effect or lymphocyte-regulating mechanism. To date, this property remains unknown, yet it may be a starting point for a potential area of further study and investigation.

Leaving aside the hypothetical assumptions of octreotide, further analysis regarding the gastric NET and the Evans Syndrome is necessary to fully understand the underlying mechanisms.
Syndrome must be made. The Evans Syndrome could be interpreted as a paraneoplastic manifestation of the gastric NET. Paraneoplastic syndromes (PNS) are characterized by anteceding the first manifestations of the proper neoplastic disease, in some cases, years before the diagnosis of the neoplastic process itself [9]. Nonetheless, the scientific literature does not describe Evans Syndrome as a typical paraneoplastic manifestation of neuroendocrine carcinomas. This association has been found in isolated and very rare cases [10]. The most common PNS associated with NETs are those caused by the overproduction of hormones, such as Cushing Syndrome, hypercalcemia, hypersecretion of cytokines and cerebellar degeneration [5, 11]. Furthermore, most PNS are dependent on the original neoplasmsomething that is not seen in this case because the scan for remnant NET gave a negative result.

Surely, the patient has a strong autoimmune background in her organism, endorsed by her diagnosis of hemolytic anemia and ITP. Considering this autoimmune background, and independent from its origin, it is possible to suspect, and only suspect, pernicious anemia (PA). PA of autoimmune origin generates a chronic atrophic gastritis [12, 13], which leads to the hyperplasia of enterochromaffin and G cells, finally predisposing the gastric tissue to the generation of metaplasia and abnormal tumoral cells [14]. Association between gastric NETs and PA has been described [15–17], yet little has been noted about the coexistence of PA and ITP [18, 19]. In this case, this patient did not have a specific workup for PA, so such diagnosis cannot be made. Nonetheless, such PA workup should have been executed based upon the patient’s intrinsic susceptibility for autoimmunity and a gastric biopsy with atrophic gastritis.

List of Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| NET          | Neuroendocrine tumor |
| 5-HIAA       | 5-Hydroxyindoleacetic acid |
| SQ           | Subcutaneous |
| CBC          | Complete blood count |
| Tc99         | Technetium-99 |
| ITP          | Idiopathic thrombocytopenic purpura |
| PA           | Pernicious anemia |
| ANA          | Antinuclear antibody |
| ANCA         | Antineutrophil cytoplasmic antibody |
| MPO          | Myeloperoxidase |
| PR3          | Proteinase 3 |

Consent

Written informed consent was obtained from the patient for publication of this paper and any accompanying images.

Conflict of Interests

The authors declare that they have no competing conflict of interests.

Authors’ Contribution

Kocfa Chung-Delgado, Sonia Guillén-Bravo, and Alejandro Revilla-Montag were responsible for the design and elaboration of the written paper. Hugo Rios-Díaz was responsible for the clinical management of the patient and the acquisition of data. José C. Alva-Muñoz performed the laboratory analysis and the clinical pathology examinations of the biopsies. Kocfa Chung-Delgado, Sonia Guillén-Bravo, Alejandro Revilla-Montag, and Hugo Ríos-Díaz proofread and drafted the final paper. All authors read and approved the final paper.

Acknowledgments

The authors thank Domingo Morales Luna, M.D., Daniel del Carpio Jayo MD and Aimeé Torres Argadoña MD for their kind contribution to the discussion and elaboration of the case report. The authors also thank Antonio Bernabe-Ortiz, M.D. for his important contribution to the elaboration of the paper.

References

[1] A. Norton and I. Roberts, “Management of Evans syndrome,” *British Journal of Haematology*, vol. 132, no. 2, pp. 125–137, 2006.
[2] D. B. Cines, J. B. Bussel, H. A. Liebman, and E. T. Luning Prak, “The ITP syndrome: pathogenic and clinical diversity,” *Blood*, vol. 113, no. 26, pp. 6511–6521, 2009.
[3] K. E. Henderson, T. J. Baranski, P. E. Bickel, W. E. Clutter, and J. B. McGill, *Endocrinology Subspecialty Consultant: The Washington Manual*, Lippincott Williams and Wilkins, Hong Kong, 2nd edition, 2009.
[4] M. A. Maggard, J. B. O’Connell, and C. Y. Ko, “Updated population-based review of carcinoid tumors,” *Annals of Surgery*, vol. 240, no. 1, pp. 117–122, 2004.
[5] G. Kalsas, I. I. Androulakis, W. W. de Herder, and A. B. Grossman, “Paraneoplastic syndromes secondary to neuroendocrine tumours,” *Endocrine-Related Cancer*, vol. 17, no. 3, pp. R173–R193, 2010.
[6] M. Michel, V. Chaton, A. Dechartres et al., “The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases,” *Blood*, vol. 114, no. 15, pp. 3167–3172, 2009.
[7] S. W. J. Lamberts, A.-J. van der Lely, W. W. de Herder, and L. J. Holland, “Octreotide,” *The New England Journal of Medicine*, vol. 334, no. 4, pp. 246–254, 1996.
[8] L. Anthony and A. I. Vinik, “Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period,” *Pancreas*, vol. 40, no. 7, pp. 987–994, 2011.
[9] L. C. Pelosof and D. E. Gerber, “Paraneoplastic syndromes: an approach to diagnosis and treatment,” *Mayo Clinic Proceedings*, vol. 85, no. 9, pp. 838–854, 2010.
[10] J. A. Giordano, “Gastric carcinoid syndrome diagnosed by endoscopy,” *American Journal of Gastroenterology*, vol. 76, no. 1, pp. 41–43, 1981.
[11] C. Christopoulos and E. Papavassiliou, “Gastric neuroendocrine tumors: biology and management,” *Annals of Gastroenterology*, vol. 18, no. 2, pp. 127–140, 2005.
[12] J. Y. Park, T. C. Cornish, D. Lam-Himlin, C. Shi, and E. Montgomery, "Gastric lesions in patients with autoimmune metaplastic atrophic gastritis (AMAG) in a tertiary care setting," *American Journal of Surgical Pathology*, vol. 34, no. 11, pp. 1591–1598, 2010.

[13] C. R. Kapadia, "Gastric atrophy, metaplasia, and dysplasia: a clinical perspective," *Journal of Clinical Gastroenterology*, vol. 36, no. 5, supplement, pp. S29–S36, 2003.

[14] H. L. Waldum, E. Brenna, and A. K. Sandvik, "Relationship of ECL cells and gastric neoplasia," *Yale Journal of Biology and Medicine*, vol. 71, no. 3–4, pp. 325–335, 1998.

[15] R. Lazarte, J. Poniachik, G. Smok, J. Contreras, L. Gutiérrez, and A. Csendes, "Clinical and endoscopic presentation of gastric neuroendocrine-tumors," *Revista Medica de Chile*, vol. 130, no. 9, pp. 985–992, 2002.

[16] A. M. E. Spoelstra-de Man, S. S. Wagenaar, A. van der Sluys Veer, and C. B. Brouwer, "Relationship between pernicious anaemia and gastric neuroendocrine cell disorders," *Netherlands Journal of Medicine*, vol. 56, no. 2, pp. 56–62, 2000.

[17] C. Lima, C. Pinho, P. Abecasis et al., "Gastric carcinoid associated with pernicious anemia," *Acta Medica Portuguesa*, vol. 5, no. 10, pp. 551–554, 1992.

[18] J. Juncá, A. Flores, M. L. Granada, O. Jiménez, and J. M. Sancho, "The relationship between idiopathic thrombocytopenic purpura and pernicious anaemia," *British Journal of Haematology*, vol. 111, no. 2, pp. 513–516, 2000.

[19] A. P. Rabinowitz, Y. Sacks, and R. Carmel, "Autoimmune cytopenias in pernicious anemia: a report of four cases and review of the literature," *European Journal of Haematology*, vol. 44, no. 1, pp. 18–23, 1990.